Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 133 clinical trials
Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer

therapy and to determine a more appropriate interval to assess hormone therapy sensitivity in women who are undergoing surgery for HR-positive, Human epidermal growth factor receptor 2 (HER2)-negative

erbb2
luminal
invasive breast cancer
ki-67
epidermal growth factor receptor
  • 1 views
  • 22 Jan, 2021
  • 1 location
Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer

investigational drug tucatinib to the standard treatment trastuzumab and capecitabine improved both progression-free survival and overall survival in people diagnosed with human epidermal growth factor 2 (HER2

  • 0 views
  • 11 Jan, 2022
  • 2 locations
T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer

does not express the human epidermal growth factor receptor 2 (HER2) protein and has spread to other places in the body (metastatic), cannot be removed by surgery (unresectable), or has come back

tubal ligation
aptt
exemestane
bisphosphonate
hormone therapy
  • 0 views
  • 20 Jan, 2022
  • 1 location
T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors

patients with cancers. They have shown promise, but have not been strong enough to cure most patients. The antibody used in this study is called anti-HER2 (Human Epidermal Growth Factor Receptor 2

malignant brain tumor
temozolomide
tumour resection
HER2
growth factor
  • 28 views
  • 17 Sep, 2021
  • 2 locations
Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease

epidermal growth factor receptor 2 (HER2) negative breast cancer with progressive disease on 2 prior lines of hormonal therapy) or triple negative (ER negative/PR negative/HER2 negative, TNBC). Eighty-four

immunostimulant
erbb2
carboplatin
mammogram
breast carcinoma
  • 3 views
  • 03 Jun, 2021
  • 11 locations
Neoadjuvant Afatinib Therapy for Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma

NSCLC.Afatinib was a 2nd-generation EGFR TKI that covalently bound and irreversibly blocked signaling through activated EGFR, human epidermal growth factor receptor 2 (HER2), and ErbB4 receptors, and the FDA has

  • 0 views
  • 29 Jan, 2021
  • 1 location
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST Advanced HER2 Positive Solid Tumors

This study is a first in human Phase 1 study that involves patients with a type of cancer called HER2 (Human Epidermal Growth Factor Receptor 2) positive cancer. This study asks patients

erbb2
bladder cancer
renal function
lung cancer
esophagus cancer
  • 0 views
  • 01 Aug, 2021
  • 1 location
Quantitative Assessment of Diffusion Spectrum Imaging in Breast Cancer

(PR), human epidermal growth factor 2 (HER-2), Ki-67, and lymphatic vessel invasion (LVI) status in breast cancer. (3) routine MRI and DSI scans were performed within one week before the pathologic

  • 0 views
  • 24 Dec, 2021
  • 1 location
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer

This study aims to evaluate the efficacy and safety of U3-1402 in participants with advanced breast cancer (ABC) and high expression of human epidermal growth factor Receptor 3 (HER3) defined as

  • 0 views
  • 22 Jul, 2021
  • 1 location
Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy

taxanes based chemotherapy is usually the first choice of NACT for human epidermal growth factor receptor 2 (HER2) negative breast cancer, but there is no ideal second-line therapy for those with

  • 0 views
  • 07 Dec, 2021
  • 1 location